Review Methylation Matters: Modeling a Manageable Genome 1 by Jared M. Ordway & Tom Curran
Review
Methylation Matters: Modeling a Manageable Genome
1
Jared M. Ordway and Tom Curran
2
Department of Developmental Neurobiology, St. Jude Children’s
Research Hospital, Memphis, Tennessee 38105
Introduction
“Chromatin can’t be important otherwise bacteria would
have it.”
—Comment made at a transcription meeting.
Transcription control was once an understandable topic.
The prevailing view was that transcription factors sought out
and bound to specific DNA sequences, thereby introducing
activators or repressors to particular target genes. Although
these interactions could erect elaborate castles on DNA, it
was possible to consider these edifices as a kind of simplistic
“Lego model.” For more than a decade, transcription regu-
lation was presented in cartoon representations of ever-
increasing Technicolor glory with DNA drawn in a straight
line. Slowly, the line began to bend as concepts dealing with
the structural packaging of DNA were considered. Today, an
accumulated wealth of data has placed chromatin structure
in a pre-eminent position in the field of transcription regula-
tion.
It used to be that discussion of chromatin was relegated to
the postbanquet morning session at conferences. Attended
by just the die-hards and the remnants of the night before
who had not yet made it back to their rooms, the talks were
often replete with rigorous science, and they sparked intense
discussion. From the field of epigenetic regulation, DNA
methylation was among the first topics to emerge onto cen-
ter stage and to be featured in plenary talks, with histone
acetylation close behind. The transcription factor “Lego”
models adopted new components, and a loose coalition was
formed between the transcription and chromatin fields. Now,
it is quite respectable to discuss the importance of chromatin
structure, DNA methylation, and histone modification to tran-
scriptional control in many biological contexts and particu-
larly in cancer. Therefore, it is worth some effort to consider
the relative contributions and to examine the cooperative
interactions among all components of the gene regulation
machinery. This is particularly pertinent if we hope to inter-
vene in the mechanisms that control gene expression to
correct the errors that result in oncogenic transformation.
Here, we will review recent progress toward understanding
the role of DNA methylation in epigenetic regulation of gene
expression, the interactions between DNA methylation and
other epigenetic systems that modulate chromatin structure,
and the relevance of these topics to cancer.
The DNA (Cytosine-5) Methyltransferases: Plotting
the Methylation Landscape
In mammals, a major form of DNA modification involves
methylation of the C5 position of cytosines within CpG
dinucleotides (1, 2). Several studies have reported the pres-
ence of 5mC
3 at non-CpG sequences (2–8), and functional
roles for these modifications have been proposed recently
(3). However, for the purpose of this review, we will focus
exclusively on the processes and functional consequences
of CpG methylation.
The distribution of CpG dinucleotides in mammalian ge-
nomes is not random. Within coding regions, CpG occurs at
a low frequency (1 CpG/100 bp), and these are predomi-
nantly methylated on both strands. However, the promoter
and 5 transcribed sequences of many genes include a re-
gion in which CpG occurs at or near the expected random
frequency (1 CpG/10 bp). These “CpG islands” tend to be
undermethylated, with the exceptions of CpG islands that
are associated with transcriptionally silent alleles of im-
printed genes and silent genes on the inactive X chromo-
some (reviewed in Ref. 4). Despite the higher frequency of
CpG methylation at these loci, CpG islands associated with
imprinted and X-inactivated genes account for 10% of total
genomic 5mC. The bulk of 5mC in the genome (70%)
resides within CpG-rich transposons scattered among ex-
tragenic and intronic sequences (5, 6).
The first eukaryotic DNA methyltransferase to be cloned,
DNA (cytosine-5) methyltransferase-1 (Dnmt1), was identi-
fied based on its biological activity (7). The Dnmt1 genomic
locus contains three known transcription start sites. A so-
matic cell-specific promoter is activated shortly after implan-
tation, and it drives expression of a transcript including a
somatic cell-specific exon (1s). Translation initiation within
exon 1s results in the full-length 1620 amino acid protein
(Dnmt1s; Refs. 8, 9). An upstream oocyte-specific promoter
drives expression of an alternative transcript including an
oocyte-specific 5 exon (1o), resulting in translation initiation
within exon 4 (8). The Dnmt1o protein contains the methyl-
transferase catalytic domain but lacks the extreme NH2-
terminal 118 amino acids of Dnmt1s. The timing of expres-
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The COOH-terminal region of Dnmt1 contains a series of
motifs characteristic of the known DNA (cytosine-5) methyl-
transferases from bacteria to humans (7, 11, 12). These
regions cooperate to form binding sites for the reaction sub-
strates, S-adenosyl-L-methionine (AdoMet) and DNA, and
the catalytic domain responsible for transfer of the methyl
donor group from AdoMet to C5 of the CpG dinucleotide.
The precise mechanism of this enzymatic reaction has been
reviewed elsewhere (10). Accumulating data have demon-
strated that the NH2-terminal region of Dnmt1 comprises
several important functional domains. These include a nu-
clear localization signal (13), a region that targets the protein
to replication foci during S phase (14, 15), sequences that
partially reduce the de novo methyltransferase activity of the
catalytic domain, and a cysteine-rich zinc-binding domain
(16, 17). As discussed below, the NH2-terminal domain also
includes sites of interaction with various proteins involved in
modulation of chromatin structure and gene regulation.
The enzymatic properties of Dnmt1 have been studied
extensively using in vitro biochemical assays as well as in
vivo genetic approaches. Although Dnmt1 can transfer a
methyl group to symmetrically unmethylated CpG dinucle-
otides in vitro, it preferentially methylates hemimethylated
target sequences. The degree of this preference ranges from
5- to 50-fold, depending on the specific study (9, 18–23), and
little if any target sequence specificity has been revealed
outside the CpG dinucleotide itself (9). These findings sug-
gest that Dnmt1 functions in the maintenance of CpG meth-
ylation by methylating the daughter strand CpG after repli-
cation of symmetrically methylated loci.
Genetic studies in mice revealed that partial loss of Dnmt1
function results in embryonic lethality. However, homozy-
gous mutant ES cells are viable, and they exhibit no obvious
growth or morphological abnormalities (24). Although these
cells exhibit substantial demethylation of endogenous retro-
viral DNA, they retain 30% of the normal level of genomic
5mC. Similar results were obtained with a complete loss-of-
function dnmt1 allele (25). Although genomic 5mC content is
reduced to levels significantly lower than those of ES cells
expressing a partial loss-of-function dnmt1 mutant, Dnmt1-
null ES cells exhibit a low level of CpG methylation. Further-
more, they retain the ability to de novo methylate newly
integrated retroviral DNA. These studies confirmed the ex-
istence of additional DNA (cytosine-5) methyltransferases
and, together with previous in vitro data, suggested that
Dnmt1 functions to maintain rather than to establish patterns
of CpG methylation.
Support for an exclusively maintenance function of Dnmt1
came from studies in which mammalian Dnmt was ex-
pressed in Drosophila (26), a species with only trace amounts
of genomic cytosine methylation (27, 28). Whereas expres-
sion of a mammalian de novo DNA methyltransferase (de-
scribed below) increased cytosine methylation, expression of
exogenous Dnmt1 did not. Co-expression of both enzymes
resulted in a 31% increase in genomic 5mC content relative
to flies expressing the de novo methyltransferase alone, pos-
sibly attributable to maintenance methyltransferase activity
of Dnmt1 on hemimethylated substrates. These data indicate
that Dnmt1 has no de novo activity in vivo. However, these
studies were carried out in cells that do not normally meth-
ylate DNA at a level comparable with that in mammalian cells.
Thus, Drosophila cells may lack additional cofactors that
direct proper de novo and maintenance cytosine methyla-
tion. A recent in vitro kinetic study suggested that the zinc-
binding domain of Dnmt1 preferentially interacts with sym-
metrically methylated DNA, and addition of symmetrically
methylated DNA stimulates zinc-dependent de novo meth-
yltransferase activity (16). Thus, in mammalian cells, Dnmt1
may catalyze the spread of CpG methylation from regions
with pre-existing methylated CpG dinucleotides into nearby
unmethylated regions. This provides a plausible alternative
explanation for the lack of Dnmt1 de novo activity in Dro-
sophila and the observation that there is a cooperative effect
of coexpression of Dnmt1 and a de novo DNA methyltrans-
ferase. Regardless, the findings outlined above demonstrate
that Dnmt1 represents the major mammalian enzyme re-
sponsible for maintenance of CpG methylation and that it is
complemented by one or more other enzymes capable of de
novo methylation.
Additional studies of cells with partial or complete loss of
Dnmt1 function revealed abnormalities in transcriptional si-
lencing of specific imprinted alleles (29), the Xist allele on the
active X chromosome (30), and endogenous retroviral ele-
ments (31). Dnmt1 activity may also play a role in modulating
rates of mutations (32, 33). The mechanisms by which Dnmt1
and presumably DNA methylation affect mutagenesis may
be complex. For example, in one study, loss of Dnmt1 ac-
tivity led to elevated rates of endogenous and exogenous
gene deletion by mitotic recombination or chromosomal loss
(34), whereas in another, Dnmt1 deficiency led to decreased
rates of missense mutations and loss of randomly integrated
marker genes (35).
The identification of Dnmt3a and Dnmt3b confirmed the
existence of a family of mammalian DNA (cytosine-5) meth-
yltransferases. These genes were identified in expressed
sequence tag databases by their sequence similarity with the
catalytic domain of Dnmt1. However, the Dnmt3 proteins
have no homology to Dnmt1 outside this region (21). The
Dnmt3a locus encodes a single protein, whereas three alter-
natively spliced Dnmt3b isoforms have been detected (21,
36). The Dnmt3 proteins contain a cysteine-rich domain re-
lated to the plant homeodomain present in many chromatin-
associated proteins. This region is most similar to the plant
homeodomain-like domain of ATRX (37), a member of the
SNF2 family of helicase/ATPases (38, 39). Interestingly, mu-
tations in ATRX cause X-linked -thalassemia mental retar-
dation (ATRX) syndrome, which is associated with both hy-
per- and hypomethylation abnormalities of specific repetitive
elements (40).
The properties of the Dnmt3 family implicated these pro-
teins as the long-awaited de novo DNA (cytosine-5) methyl-
transferases. Unlike Dnmt1, neither Dnmt3a nor Dnmt3b
shows a preference for hemimethylated DNA target sites in
vitro (21, 36). Furthermore, the expression patterns of the
Dnmt3 genes correlate with the timing of developmental de
novo methylation. Although Dnmt1 is expressed ubiquitously
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level in undifferentiated embryonic stem cells but at low
levels in differentiated somatic tissues (21). The de novo
methyltransferase functions of Dnmt3a and Dnmt3b have
been confirmed by studies in genetically modified mice.
Okano et al. (41) produced embryonic stem cell lines with
homozygous null mutations in Dnmt3a and Dnmt3b, sepa-
rately and in combination. Both single knock-out lines re-
tained the ability to methylate foreign retroviral DNA, whereas
the double knock-out cells completely lacked this activity,
demonstrating both the requirement and the redundancy of
Dnmt3a and Dnmt3b for de novo methyltransferase activity.
Despite their overlapping patterns of expression and their
largely redundant functions, the effects of independent loss
of the two enzymes demonstrate that the two enzymes have
distinguishable functions. Mice deficient in Dnmt3a survive
to term, but they become runted and die at 4 weeks of age.
However, Dnmt3b
/ embryos develop normally before em-
bryonic day (E) 9.5, but they die prior to term. Embryos
lacking both enzymes show abnormal morphology by E8.5,
and they die by E11.5. Genomic methylation abnormalities in
these embryos further demonstrate both overlapping and
specific functions of the Dnmt3 family. For example, C-type
retroviral DNA and intracisternal A particle repeats are unaf-
fected (Dnmt3a
/) or only slightly undermethylated
(Dnmt3b
/) in single knock-out embryos, but they are sub-
stantially undermethylated in double knock-out embryos.
However, the overall methylation level in double knock-out
embryos remains higher than the level in embryos lacking
Dnmt1. Centromeric minor satellite repeats are significantly
demethylated in Dnmt3b
/ cells but unaffected in
Dnmt3a
/ cells, suggesting that this class of sequence is
methylated specifically by Dnmt3b.
The identification of mutations responsible for ICF (immu-
nodeficiency, centromeric region instability, and facial anom-
alies) syndrome provided a natural demonstration of target
specificity for Dnmt3b (41–43). This genetic disorder is char-
acterized cytogenetically by marked hypomethylation of spe-
cific classical satellite repeats (44, 45), elongation of juxta-
centromeric heterochromatin in lymphocytes, and various
structural abnormalities involving chromosomes 1, 9, and 16
(46). Therefore, although none of the known DNA (cytosine-5)
methyltransferases show target specificity in vitro, mecha-
nisms exist to direct their activity to appropriate genomic loci
in vivo. This is currently an exciting area of research, and as
discussed below, the recent identification of key molecules is
beginning to shed light on critical pathways that regulate
DNA methylation.
The Methyl-binding Proteins: Linking DNA
Methylation and Chromatin Structure
The correlation between DNA methylation and transcriptional
inactivity is well established. However, a causative role for
CpG methylation in repression of transcription has often
been a subject for debate. Although many silenced genes are
associated with dense CpG methylation, this epigenetic
mark could be a downstream consequence of transcriptional
inactivity rather than an active participant in the process of
repression. However, the identification of a family of proteins
that bind to DNA containing methylated CpG dinucleotides
established a causative link between CpG methylation and
repression of transcription. The members of this family have
been comprehensively reviewed (47–50). Therefore, we will
briefly discuss the general characteristics of the mammalian
family members.
The presence of methyl-CpG-binding proteins in human
cell extracts was demonstrated nearly two decades ago (51).
MeCP2 was the first individual component of these com-
plexes to be purified and biochemically characterized (52,
53). This protein contains an NH2-terminal MBD (54) and a
COOH-terminal TRD (55). It associates with chromatin (53)
and localizes to methyl-CpG-rich sequences in vivo (56). In
vitro, the intact protein or the MBD alone selectively binds to
DNA containing symmetrically methylated CpG dinucleo-
tides with an affinity directly proportional to methyl-CpG
density (52, 57). Likewise, the TRD represses transcription
independently of other MeCP2 sequences (54, 58–60). Bind-
ing of the Sin3a corepressor to the TRD recruits HDAC into
the complex (58, 59). These findings provide a conceptual
framework for a chain of events by which DNA methylation
actively promotes transcriptional silencing. According to the
model, MeCP2 binds to chromosomal regions containing
methylated CpG dinucleotides. A histone deacetylase core-
pressor complex is then recruited by the binding of Sin3a/
HDAC to MeCP2. Histone deacetylation, in turn, results in
condensation of chromatin leading to a local chromatin
structure that is refractory to initiation of transcription
(reviewed in Ref. 50). Consistent with this model, in vitro
transcription repression by MeCP2 is sensitive to histone
deacetylase inhibitors (58, 59). However, the complexity of
interactions among members of both the methyltransferase
and MBD families suggests that this pathway may be one
of several intersecting pathways leading to methylation-
dependent transcription repression. In fact, there is evidence
for HDAC-independent mechanisms of transcription repres-
sion by MBD proteins, further extending the potential impact
of DNA methylation on gene expression (47, 60–62). Further-
more, in colorectal carcinoma and in leukemic cell lines,
hypermethylated, transcriptionally silent genes can be reac-
tivated by simultaneous treatment with the HDAC inhibitor
TSA and the demethylating agent 5-Aza-dC but not by TSA
alone (63). These findings suggest either that DNA methyla-
tion has additional repressive effects that are independent of
histone deacetylation, or that unknown TSA-insensitive
HDACs are also involved.
Additional MBD-containing proteins have been identified
through an in silico approach to cloning (64, 65). Five MBD
family members have now been identified. MBD1 has an
NH2-terminal MBD and a COOH-terminal TRD. In addition,
full-length MBD1 contains three CXXC motifs similar to the
motif present in Dnmt1 (64). MBD1 binds preferentially to
densely methylated DNA in vitro, and it represses transcrip-
tion in a HDAC-dependent manner in transfected cells (64,
66, 67). Consistent with its in vitro DNA binding characteris-
tics, overexpressed green fluorescent protein-tagged MBD1
localizes to densely methylated major satellite DNA in mouse
cells (65), and it is concentrated at methylated pericentro-
meric regions of chromosome 1 in human cells (68). Endog-
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man diploid metaphase chromosome spreads, but it
concentrates at centromeric heterochromatic regions of
chromosomes 1, 9, 15, and 16, as well as regions of densely
methylated spacer DNA sequences interspersed among
rRNA genes. Furthermore, the intensity of MBD1 staining is
generally inversely proportional to the staining intensity of
acetylated histone H4 (66). In human cells, MBD1 mRNA is
expressed as five alternatively spliced forms that encode
isoforms differing in their COOH-terminal and CXXC regions
(65, 68). Although the functional consequences of these al-
ternative forms are unclear, inclusion of all three CXXC motifs
results in an MBD1 isoform capable of repressing transcrip-
tion independently of DNA methylation in transfected cells
(67, 68).
MBD2 includes partially overlapping MBD and TRD do-
mains (69). The MBD binds to DNA with a single methylated
CpG in vitro (65, 70), and an MBD2-GFP fusion protein binds
to major satellite DNA in transfected mouse cells (65). Con-
sistent with an HDAC-dependent model of gene repression,
the TRD exhibits TSA-sensitive transcription repression ac-
tivity in reporter assays (62). Ng et al. (62) identified MBD2 as
the methyl-binding component of the MeCP1 complex, a
methyl-CpG-binding activity that is distinguishable from
MeCP2 in that MeCP1 requires more densely methylated
DNA for binding (71). MeCP1 was recently suggested to
comprise a chromatin remodeling ATPase (NuRD) complex
with associated HDAC activity (62, 72). Furthermore, MBD2
has been reported to be associated with Sin3a (69). It is likely
that the variation in reported factors and complexes associ-
ated with MBD2 reflects several distinct yet overlapping cell
context-dependent functions of this family of proteins.
MBD3 has extensive sequence similarity to MBD2 (65). It is
expressed as several splice variants, some of which disrupt
the MBD (65, 73). The protein has been identified as a com-
ponent of the Mi-2/NuRD transcriptional corepressor com-
plex that includes Mi-2 ATPase, HDAC, and other proteins
(70, 73, 74). However, in vitro, mammalian MBD3 has little if
any methyl-CpG-binding activity, likely because of amino
acid substitutions within the MBD (65, 70). Therefore, unlike
the case for the Xenopus orthologue of MBD3 which con-
tains a MBD with methyl-CpG-binding activity (70), it is un-
likely that mammalian MBD3 plays a role in methylation-
dependent transcription repression.
Finally, MBD4 includes a MBD similar to that of MeCP2,
although the COOH-terminal domain is homologous to bac-
terial DNA repair enzymes (65). Although MBD4 is capable of
binding to methyl-CpG sites, it has a higher affinity for
5mCpG-TpG mismatched sites (75), and the DNA repair
domain provides DNA N-glycosylase activity at G-T mis-
matches (75, 76). Therefore, MBD4 is ideally suited to func-
tion in the repair of point mutations that result from sponta-
neous deamination of 5-methylcytosine to thymine. In
addition, MBD4 (also known as MED1) binds to the MLH1
DNA mismatch repair protein in vivo. Expression of a MBD4
mutant lacking the MBD induces microsatellite instability in
cell lines, implicating MBD4 in this form of DNA repair as well
(77). These data suggest that MBD4 may serve as a strand
discrimination factor for MLH1, directing mismatch repair
activity to the newly synthesized strand. However, in an in
vitro assay, nuclear extracts containing MBD4 perform mis-
match repair independently of target CpG methylation status
(78).
Chromatin Cross-Talk
Collectively, the studies reviewed above have contributed to
a basic understanding of the enzymes that establish and
maintain CpG methylation, as well as mechanisms by which
these epigenetic signals are interpreted. However, much re-
mains to be sorted out, and recent findings have added
additional layers of complexity to the pathways involved. A
productive approach toward understanding the regulation of
DNA methylation has been the search for proteins that inter-
act with the methyltransferases (reviewed in Ref. 79). Be-
cause Dnmt1 was the first mammalian (cytosine-5) methyl-
transferase to be identified, it remains the most extensively
studied to date. PCNA, a DNA polymerase processivity fac-
tor required for DNA replication (80), binds to an NH2-termi-
nal region of Dnmt1 (15). PCNA is recruited to sites of rep-
licating DNA by CAF-1 p150, a factor responsible for
assembly of nucleosomes onto replicating DNA (81). The
interaction of PCNA with Dnmt1 therefore provides an at-
tractive mechanism by which Dnmt1 is directed to sites of
newly replicating DNA to maintain full methylation status
after replication (82).
In addition to the indirect recruitment of HDACs via MBD
proteins, Dnmt1 interacts directly with HDAC1 and HDAC2
(83–85). This interaction may provide an additional associa-
tion between DNA methylation and chromatin condensation
by bringing the factors required for both into proximity. The
association of HDAC with MBD proteins may then serve a
maintenance-repressive role by keeping histones in a
deacetylated state independently of Dnmt1. As discussed
below, factors involved in histone modification and chroma-
tin remodeling may also establish a local chromatin structure
that provides the DNA methylation machinery access to DNA
targets.
Rountree et al. (85) identified a novel protein, DMAP1, that
binds to the extreme NH2-terminus of Dnmt1. When fused to
a generic DNA binding domain, DMAP1 functions as an
HDAC-independent transcriptional repressor, possibly ac-
counting for at least some of the HDAC-independent repres-
sion ability of Dnmt1 (83, 85). Dnmt1 has also been shown to
exist in complex with the pRb tumor suppressor and the
pRb-associated E2F-1 transcriptional activator in vivo (84). In
nondividing cells, pRb binds to E2F-1 and represses trans-
activation of genes involved in cell cycle progression (86).
Additionally, pRb binds to HDAC (87). The interaction of
Dnmt1 with pRb may enhance its repressive effects by tar-
geted methylation of E2F-1 binding sites or by recruitment of
histone deacetylases to these loci.
These discoveries demonstrate that Dnmt1 is linked to
several pathways associated with transcription repression.
Ongoing studies of the other DNA (cytosine-5) methyltrans-
ferase family members will certainly provide additional in-
sights into the complex relationship between these enzymes
and the regulation of gene expression. In fact, Fuks et al. (88)
recently demonstrated that Dnmt3a binds RP58, a transcrip-
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promoters of various tissue-specific genes, potentially pro-
viding a mechanism for sequence-specific targeting of the
enzyme (89). Dnmt3a also directly interacts with HDAC1 (88).
Although the interactions of DNA (cytosine-5) methyltrans-
ferases with sequence-specific DNA binding factors may
target the activity of these enzymes to some degree, the
identified interactions do not explain how global DNA meth-
ylation patterns are precisely established. DNA (cytosine-5)
methyltransferases must establish and maintain the methy-
lation status of appropriate sequences (repetitive elements,
imprinted alleles, and others) while other critical CpG-rich
sequences remain unmethylated (CpG islands of transcribed
genes). Recent studies have begun to shed light on these
mechanisms, revealing additional levels of complexity and
interdependence associated with DNA methylation and
chromatin structure.
Although the effect of CpG methylation on transcription is
mediated largely by histone-modifying factors, it is now ap-
parent that chromatin remodeling factors are also involved in
regulation of the global methylation pattern. In Arabidopsis
thaliana, the ddm1 (decrease in DNA methylation 1) mutant
exhibits a 70% reduction of genomic cytosine methylation
involving mostly repetitive sequences (90). Decreased meth-
ylation of low-copy sequences occurs over multiple gener-
ations (91). DDM1 is a member of the SNF2-like ATPase/
helicase family of proteins that catalyze ATP-dependent
disruption of histone-DNA interactions (92). A model was
proposed in which nucleosome remodeling is essential for
the establishment and maintenance of DNA methylation,
possibly by allowing the methylation machinery access to
DNA targets (Fig. 1). An analogous system was subsequently
identified in mammals. Homozygous disruption of lymphoid-
specific helicase, Lsh (also known as PASG, proliferation-
associated SNF2-like gene), results in perinatal lethality in
mice (93) and 50% reduction in global cytosine methylation
content affecting repetitive elements and CpG islands asso-
ciated with select imprinted alleles (94). Lsh, which is ubiq-
uitously expressed primarily during S-phase, is closely re-
lated to the SNF2 subfamily. It contains ATPase and helicase
domains similar to those of Arabidopsis DDM1 and other
proteins in yeast, mice, and humans (reviewed in Ref. 95).
Recent studies of DNA methylation in Neurospora crassa
may also provide insight into the regulation and functional
role of DNA methylation in mammals. In a genetic screen for
mutants with decreased genomic cytosine methylation,
Kouzminova and Selker (96) identified dim-2, a DNA meth-
yltransferase responsible for both de novo and maintenance
cytosine methylation. A subsequent insertional mutagenesis
strategy fortuitously generated a mutation in an independent
gene, dim-5, that is also essential for cytosine methylation.
Surprisingly, this gene encodes a protein methyltransferase
that specifically methylates lysine 9 of histone H3 (H3-Lys9;
Ref. 97). The protein is homologous to the H3-Lys9 methyl-
transferases of Saccharomyces pombe (Clr4), Drosophila,
and humans (Suv39h; Ref. 98). Consistent with the require-
ment of H3-Lys9 methylation for DNA cytosine methylation,
expression of histone H3 mutants with amino acid substitu-
tions of Lys9 results in decreased genomic cytosine methy-
lation in a wild-type strain (97). Adding yet another level of
regulation to the system, methylation of histone H3-Lys9 is
itself an epigenetic mark of heterochromatin. The mechanism
involves binding of heterochromatin protein 1 (HP1, reviewed
in Refs. 99, 100) to Lys9-methylated histone H3, resulting in
chromatin remodeling and gene silencing (101–104). If there
is also a requirement for histone H3-Lys9 methylation for
DNA methylation in mammalian cells, this suggests that an
interplay of DNA and protein modifications may mediate the
establishment and maintenance of DNA methylation as well
as the epigenetic modulation of transcription repression
(Fig. 1). The ultimate target of these events is the nucleo-
some. For example, ATP-dependent nucleosome remodel-
ing factors (i.e., Lsh) may be required to loosen DNA-histone
contacts, facilitating access of DNA (cytosine-5) methyl-
transferases to target DNA sequences. Simultaneously, his-
Fig. 1. Various factors affect DNA methylation-associated transcription
repression. A, SNF2-like ATPases (i.e., Lsh) loosen DNA-histone contacts.
Histone methyltransferases (i.e., Suv39H1) methylate lysine 9 of histone
H3 (stars). B, these modifications may lead to a chromatin configuration
that is permissive for CpG methylation. C, sequence-specific DNA-bind-
ing factors may target DNA (cytosine-5) methyltransferases to appropriate
loci. Examples of potential Dnmt1 targeting factors include pRb and
PML-RAR. Dnmt1 directly binds to HDACs, which are also complexed
with MBD proteins such as MeCP2. Dnmt1 associates with DMAP1, a
putative HDAC-independent transcription repressor. D, DNA (cytosine-5)
methyltransferases catalyze CpG methylation (filled circles), creating bind-
ing sites for MBD proteins. E, MBD proteins may remain associated with
the methylated loci, allowing chromatin condensation independently of
DNA (cytosine-5) methyltransferases.
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lishment of nucleoprotein complexes that recruit DNA
(cytosine-5) methyltransferases to target loci or remodel
chromatin into conformations permissive for DNA methyla-
tion. Alternatively, these processes may be linked to protec-
tion against DNA demethylation rather than the establish-
ment or maintenance of DNA methylation. Finally, the
epigenetic territorial markers, CpG and H3-Lys9 methylation,
also recruit factors that further modify histones, resulting in
locally condensed, transcriptionally silent heterochromatin.
The studies summarized above suggest that disruptions
within chromatin modification pathways affect highly repet-
itive, constitutive heterochromatin. However, precise epige-
netic patterns must also be established at low-copy loci. For
example, CpG methylation and histone H3-Lys9 methylation
associate with the facultative heterochromatin of the inactive
X chromosome and promoters of specific X-inactivated
genes (105, 106). Furthermore, reminiscent of its potential
targeting function for Dnmt1, pRb has recently been shown
to bind to both Suv39H1 and HP1, directing their activities to
the cyclin E promoter (107). Finally, genetic inactivation of an
unconventional member of the Dnmt family revealed a role in
targeting de novo methylation. Dnmt3L has extensive homol-
ogy to Dnmt3a and Dnmt3b, but it lacks a functional DNA
methyltransferase catalytic domain (108). Bourc’his et al.
(109) recently produced mice lacking functional Dnmt3L.
This mutation behaves as a maternal effect lethal. Homozy-
gous mutant males are viable, but sterile. Homozygous fe-
males are fertile, yet their heterozygous offspring die before
term. Surprisingly, these mutant embryos exhibit a very spe-
cific DNA methylation abnormality. They lack the ability to
properly methylate maternally repressed imprinted genes
(Snrpn and Peg1), yet they maintain proper allele-specific
methylation of the paternally methylated H19 gene. There-
fore, Dnmt3L is required for the de novo establishment, but
not maintenance, of specific genomic imprints. It is likely that
Dnmt3L functions not as a methyltransferase but instead as
a regulatory cofactor that directs the activity of other meth-
yltransferase(s) to appropriate targets.
These findings raise many additional questions concerning
the interdependence of pathways leading to chromatin re-
modeling and regulation of transcription. Such elaborate reg-
ulatory networks present many potential points of deregula-
tion (Fig. 2). Further elucidation of the mechanisms involved
will likely increase our understanding of the process and
consequences of CpG methylation, and they may uncover
currently unrecognized avenues leading to tumorigenesis.
DNA Methylation Abnormalities in Tumors
At a simplistic level, tumorigenesis arises as a consequence
of two related events, increased activity of factors that pro-
mote cell proliferation and decreased activity of factors that
suppress unchecked proliferation. These basic scenarios
demonstrate the involvement of both activating and inacti-
vating mechanisms in tumorigenesis. However, additional
abnormalities must accompany (or even supercede) changes
in proliferative capacity for a transformed cell to cause ma-
lignancy. For example, transformed cells acquire the ability
to invade surrounding tissue and travel long distances to
establish themselves in new environments. They remodel
local vasculature to feed aggressively growing cells, they
circumvent intrinsic surveillance cell death mechanisms, and
they impair DNA repair systems. Therefore, cancer involves
not only aberrant proliferation but also subversion of mech-
anisms involved in the regulation of cell-cell and cell-matrix
attachment, growth factor signaling, apoptosis, and recom-
bination. In terms of inactivation of tumor suppressor genes,
Knudson’s “two-hit” hypothesis is a cornerstone concept.
DNA mutations and chromosomal loss or rearrangements
have traditionally received the most attention. However,
given the number of pathways altered during creation of an
environment permissive for tumorigenesis, processes linked
to DNA methylation, provide additional potential mecha-
nisms leading to heritable genomic changes that promote
cancer.
The discovery of global CpG methylation abnormalities in
tumors led to the initial implication of a role of DNA methy-
lation in cancer (110, 111). Tumor cells may harbor simulta-
neous hypermethylation of specific CpG islands and global
hypomethylation of widespread transposon elements. Po-
tentially, both events play active roles in tumorigenesis. Al-
though precise mechanisms have not yet been demon-
strated, DNA methylation may protect the genome by
inhibiting homologous recombination between highly repet-
itive sequences (112). Therefore, loss of DNA methylation at
these loci may increase the frequency of inappropriate re-
combination leading to chromosomal abnormalities preva-
lent in tumors. This hypothesis is supported by the finding
that ES cells lacking functional Dnmt1 have a 10-fold higher
mutation rate involving gene rearrangements than wild-type
ES cells (34). Because cytosine methylation increases the
frequency of C-to-T point mutations attributable to deami-
nation of 5mC to uracil, CpG methylation may play a passive
role in promoting point mutations. For example, a high fre-
Fig. 2. Relationships among the CpG methylation and chromatin remod-
eling machinery. Lightning bolts, potential points of deregulation that
could alter CpG methylation patterns and gene expression in tumors. See
text for details.
154 DNA Methylation, Chromatin Structure, and Cancerquency of p53 mutations occur at presumably methylated
exonic CpG sites (113, 114). Regarding hypermethylation of
specific CpG islands, several transcriptionally silent genes
exhibit dense CpG island methylation in tumors and tumor
cell lines, suggesting that these events either initiate tran-
scription silencing, or they participate in maintaining genes in
a repressed state. As reviewed by Baylin and Herman (115),
nearly half of the tumor suppressor genes carrying germ-line
mutations in familial cancers have been shown to be inacti-
vated in association with CpG island hypermethylation in
sporadic cancers. These include VHL, p16
INK4a, pRb, ARF/
INK4a, and several others. Equally telling, the list to date
includes genes whose protein products participate in many
processes required to create a microenvironment suitable for
tumorigenesis and metastasis. Among these are genes that
function in suppression of invasion (E-cadherin, mts-1, and
others), inhibition of angiogenesis (Thrombospondin-1,
TIMP3), apoptosis (DAPK1, Fas) and DNA protection or re-
pair (O
6-MGMT, hMLH1, GSTP1, and BRCA-1). Genes si-
lenced in association with hypermethylation in various tumor
types have been reviewed (79, 115–117). This group likely
represents only a fraction of the aberrant methylation events
potentially important in cancer. Furthermore, the current list
probably reflects an ascertainment bias toward genes with
previously demonstrated roles in tumorigenesis, because of
the candidate gene approach traditionally used for identifi-
cation of methylation abnormalities. Consequently, unbiased
approaches for identification of methylation changes asso-
ciated with cancer have been established recently.
Methylated CpG island amplification identifies differentially
methylated loci based on their ability to be amplified by PCR
subsequent to digestion by methylation-sensitive restriction
enzymes (118). Parallel methylated CpG island amplification
of tumor and normal DNA, followed by representational dif-
ference analysis (119), can identify a pool of genomic frag-
ments differentially methylated in the tumor samples. Toyota
et al. (120) screened 50 colorectal cancers and 15 colonic
adenomas for methylation changes at 30 candidate loci iden-
tified by MCA. The authors found that the majority of CpG
island hypermethylation events occurred at loci incremen-
tally hypermethylated in normal colonic tissue during the
aging process, demonstrating a concordance between tu-
mor-associated DNA hypermethylation and methylation
changes that occur during the normal aging process. Addi-
tionally, a tumor subgroup emerged that displayed a CpG
island methylator phenotype (CIMP), potentially equivalent to
genomic instability in terms of effects on gene expression.
The hypermethylation profile of CIMP colorectal tumors
included loci unique to tumor tissues and distinguished the
majority of sporadic colon cancers with microsatellite insta-
bility related to hMLH1 hypermethylation. Further analyses of
CIMP and CIMP colorectal tumors demonstrated that
methylation status correlated with the mutation status of p53
and K-RAS, suggesting direct links between genetic and
epigenetic pathways in tumorigenesis (121).
Differential methylation hybridization (DMH) (122) com-
bines methylated CpG island amplification with hybridization
of amplicons from tumor and normal controls to an arrayed
library of genomic CpG island fragments (57). In a differential
methylation hybridization study of primary breast tumors,
cluster analyses revealed an association between wide-
spread CpG island methylation patterns and histological tu-
mor classification whereby poorly differentiated tumors gen-
erally displayed more extensive hypermethylation than
moderately or well-differentiated tumors (123).
These studies suggest that elucidation of genome-wide
“DNA methylation signatures” of normal, preneoplastic, and
tumor tissues is essential for understanding the role of DNA
methylation in cancer. A technique based on restriction land-
mark genomic scanning (RLGS) (124) has recently produced
promising results toward these goals (125–128). Methyla-
tion-sensitive restriction landmark genomic scanning in-
volves digestion of genomic DNA with methylation-sensitive
enzymes, followed by resolution of differentially digested
fragments by two-dimensional gel electrophoresis. Compar-
ison of gel migration profiles obtained from normal and tumor
samples allows identification of aberrantly methylated loci.
This technique was used to analyze the methylation status of
1184 CpG islands in 98 primary human tumors (125). The
authors found that on average, 600 CpG islands are aber-
rantly methylated in tumors. As suggested by studies of
substantially smaller sets of CpG island loci, the results un-
covered global nonrandom patterns of methylation in tu-
mors, with specific methylation events associated with par-
ticular tumor types.
Within the past few years, microarray-based approaches
have allowed simultaneous analysis of mRNA expression
levels representing thousands of genes. Likewise, array-
based strategies are being adapted for high-throughput
analysis of DNA methylation patterns (129, 130). Although
these technologies are in their infancy, the implications are
evident. One can envision a future in which global signatures
of the epigenome, transcriptome, and proteome are mapped
for various conditions, providing unprecedented tools for
cancer diagnostics, prognostics, and therapeutics.
DNA Hypermethylation and Cancer: Cause
or Effect?
The initial proposal that DNA methylation plays a direct role
in transcriptional regulation was met with skepticism. Simi-
larly, the concept that aberrant DNA methylation plays a
direct role in tumorigenesis was not immediately embraced
by the field. It is now clear that DNA methylation can actively
participate in transcriptional repression in several ways. Fur-
thermore, hypermethylation of CpG islands associated with
transcriptionally silent genes is featured in many tumors.
However, questions remain regarding the causative role of
CpG island hypermethylation in tumorigenesis. Because tu-
mor cells represent the final state of a complex process
leading to cancer, these questions are often difficult to an-
swer. Several observations suggest that DNA methylation
abnormalities represent more than simple markers of trans-
formation. For example, in particular familial or sporadic
cancers, hypermethylation is the sole detectable explanation
for complete loss of expression and activity of pRb, VHL,
BRCA1, or p16
INK4a tumor suppressor genes (reviewed in
Refs. 79, 115, 117)). Using a high-throughput candidate gene
approach based on methylation-specific PCR, Esteller et al.
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in which one allele of a particular tumor suppressor gene was
mutated and the remaining allele was lost, the retained mu-
tant allele was never hypermethylated. However, in tumors in
which both the mutated and the wild-type allele were re-
tained, DNA hypermethylation served as a frequent “second
hit” to inactivate the functional allele. These findings dem-
onstrate a powerful selective force for methylation-associ-
ated inactivation independent of genetic mutation (131).
Other examples suggest that DNA hypermethylation can ac-
tually promote genetic instability. The DNA repair gene
hMLH1 is frequently hypermethylated in sporadic colorectal
carcinomas with microsatellite instability. Treatment of cell
lines derived from these tumors with the demethylating agent
5-Aza-dC results in re-expression of hMLH1 and partial res-
toration of mismatch repair activity (132). Finally, CpG meth-
ylation changes can occur very early in tumorigenesis. Hy-
permethylation of p16
INK4a in lung cancer has been detected
in preneoplastic cells, the degree of which is directly propor-
tional to disease progression (133–135).
Although these findings establish a strong correlation be-
tween tumorigenesis and hypermethylation of specific tumor
suppressor genes, confirmation of a causative relationship
awaits demonstration of the precise mechanisms of aberrant
DNA methylation and analysis of their functional conse-
quences throughout the process of cellular transformation.
One potential mechanism is up-regulated expression of the
DNA (cytosine-5) methyltransferase themselves. Kautiainen
and Jones (136) demonstrated increased DNA methyltrans-
ferase activity in various tumorigenic cell lines relative to
nontumorigenic cells. Subsequently, increased DNA methyl-
transferase activity was shown to coincide with increased
expression of DNMT1 in human neoplastic cells and tumor
tissues, and the magnitude of expression increased with
progressive stages of disease (137, 138). Forced overex-
pression of a mouse Dnmt1 cDNA results in increased
genomic DNA methylation and induction of cellular transfor-
mation and tumorigenic potential of NIH 3T3 cells (139). In
fibroblasts transformed by overexpression of human
DNMT1, de novo methylation of particular CpG islands oc-
curs within 70 population doublings (140). More recently,
elevated expression of the DNMT3b (141) and decreased
expression of MeCP2 and MBD2 (142) in tumors have been
reported. Furthermore, in some colorectal carcinomas with
microsatellite instability, frameshift mutations arising from
small insertions or deletions within an (A)10 tract in the coding
region of MBD4 have been detected (143, 144). The frame-
shift mutations could lead to expression of a truncated form
of MBD4 that includes the MBD but lacks the DNA repair
domain. This could potentially enhance mutagenesis in
tumors with microsatellite instability because of a dominant-
negative effect of the truncated protein (143) or complete
inactivation of MBD4 function by loss of heterozygosity (144).
Evidence for a functional role of Dnmt1 in tumorigenesis
has also been obtained using genetically modified mice. The
Min mouse, a valuable model of intestinal cancer, is het-
erozygous for a germ-line mutation in the adenomatous pol-
yposis coli (Apc) gene. Human APC is mutated (145) or
associated with promoter hypermethylation (146) in the ma-
jority of colon cancers, a disease in which promoter hyper-
methylation of several genes has been reported. On the B6
mouse genetic background, heterozygosity for the Min allele
predisposes to development of hundreds of intestinal ade-
nomas (147). Laird et al. (148) demonstrated that crossing
B6-Min/ mice to mice with one mutated Dnmt1 allele (129/
SvJ-Dnmt1
S/) results in a dramatic decrease in the fre-
quency of intestinal adenomas. Early treatment of these mice
with 5-Aza-dC resulted in further reduction of tumor inci-
dence by nearly 60-fold (148). By crossing B6-Min/ mice to
the homogeneous B6-Dnmt1
N/ strain, Cormier and Dove
(149) found that the effect of Dnmt1 deficiency on tumor
incidence and growth is independent of the status of p53 or
modifier of Min 1 (Mom1), two loci that confer strong resist-
ance to Min-induced intestinal tumorigenesis. Interestingly,
although Dnmt1 deficiency and Mom1 affect tumorigenesis
independently, together they act synergistically to reduce
tumor incidence by 40-fold, and they completely prevent
tumor development in nearly half of the mice studied (149).
Mechanistically, overexpression of Dnmt1 has been asso-
ciated with transforming oncogenes including ras (150, 151),
SV40 large T-antigen (152), and fos (153), suggesting that
increased expression of Dnmt1 may play a role in cellular
transformation. In these model systems, up-regulation of
Dnmt1 expression and activity appears to be necessary for
complete cellular transformation because antisense inhibi-
tion of Dnmt1 expression leads to restoration of nontrans-
formed cellular morphology and growth properties
(152–155), and it decreases tumorigenic growth of trans-
formed cells in syngeneic mice (154, 155). Additionally, treat-
ment of fos-transformed fibroblasts with TSA results in re-
version to a more normal cellular morphology, implicating
chromatin remodeling in aspects of the transformed pheno-
type (153). Importantly, steady-state Dnmt1 mRNA levels
vary during the cell cycle, increasing in parallel with prolifer-
ation (156). Therefore, elevation of Dnmt1 levels has been
proposed to simply reflect the increased proliferative capac-
ity of transformed cells (10, 157, 158). However, studies of
the role of Dnmt1 in cellular transformation by fos demon-
strated that increased expression and activity of Dnmt1 can
be uncoupled from cell cycle regulation. Enforced expres-
sion of fos in cultured fibroblasts results in morphological
cellular transformation independently of cell proliferation
(159). In growth-arrested fibroblasts, ectopic induction of
c-fos expression results in morphological transformation, in-
creased expression of the endogenous Dnmt1 gene, ele-
vated DNA methyltransferase activity, and increased
genomic 5mC content (153). When ectopic expression of
c-fos is repressed, these cells revert to a nontransformed
morphology, Dnmt1 expression and activity decrease, and
genomic 5mC content returns to basal levels. Intriguingly,
these results demonstrate that genomic 5mC content can be
both increased and decreased independently of cell division,
implying that an active demethylation process functions dur-
ing reversion of fos transformation. Indeed, an isoform of the
MBD2 protein has been reported to possess 5mC demethy-
lating activity in vitro (160). This finding implies that MBD2
may possess bimodal functions involving both methylation-
dependent transcriptional repression and modulation of pre-
156 DNA Methylation, Chromatin Structure, and Cancercise DNA methylation patterns. However, the demethylating
ability of MBD2 has been disputed (62, 70).
These results demonstrate a potential proliferation-inde-
pendent role for increased Dnmt1 activity during oncogenic
transformation. However, because transformation requires
continued oncogene expression, the relevant defect may lie
in sustained activity of DNA (cytosine-5) methyltransferases
within an inappropriate cellular context rather than in the
absolute level of Dnmt1. Consistent with this possibility, DNA
methyltransferase activity decreases during G0-G1 arrest of
normal bladder fibroblasts, yet bladder tumor cells maintain
a higher level of methylation activity throughout the period of
growth arrest (161). Furthermore, the Dnmt1 isoform ex-
pressed in tumors has not been shown to independently
induce cellular transformation or tumorigenesis. The studies
described above in which ectopic expression of Dnmt1 in-
duced cellular transformation and tumorigenesis used an
NH2-terminally truncated form of Dnmt1 (Dnmt1o) corre-
sponding to the oocyte-specific version of the enzyme (139,
140, 153). In our hands, overexpression of the full-length
somatic isoform of Dnmt1 (Dnmt1s) induces cell death rather
than cellular transformation.
4 Yet, during cellular transforma-
tion by ras, SV40 large T-antigen or fos, the endogenous
somatic Dnmt1 isoform is necessary for full cellular transfor-
mation (152–155) and tumorigenic potential (154, 155).
Therefore, it appears that deregulation of Dnmt1 activity
participates in transformation only in cells in which onco-
genic pathways have been activated. This implies that the
mechanisms involving Dnmt1 (including but not restricted to
DNA methylation) must interact with additional cellular pro-
cesses to participate in transformation. The fact that the
oocyte-specific form of Dnmt1, which lacks an NH2-terminal
region that participates in various protein-protein interac-
tions, can induce transformation and tumorigenesis may di-
rect attention toward converging pathways linking Dnmt1 to
mechanisms of tumorigenesis.
A recent study of the mechanisms of transcription repres-
sion by PML-RAR suggests a link between DNA (cytosine-5)
methyltransferases and an oncogenic transcription factor
fusion that is independent of the level of Dnmt1 expression
(162). In 90% of APL cases, a reciprocal chromosomal
translocation involving PML and the RA receptor RAR leads
to expression of an oncogenic PML-RAR fusion transcription
factor (163, 164). PML-RAR functions as a repressor of RA
target gene transcription through a mechanism involving re-
cruitment of an HDAC complex, resulting in a block in the
differentiation of APL blasts (165). Di Croce et al. (162) found
that induction of PML-RAR results in increased CpG meth-
ylation in the 5 region of the RA receptor RAR2, a gene
repressed by PML-RAR. Physical interactions between PML-
RAR and either Dnmt1 or Dnmt3a were detected by coim-
munoprecipitation in an inducible PML-RAR expression cell
line and in APL-derived cells. In the presence of PML-RAR,
Dnmt1 and Dnmt3a are recruited to the RAR2 promoter,
and the proteins colocalize in transfected cells. Furthermore,
RA and 5-Aza-dC act synergistically to reduce RAR2 CpG
methylation and reactivate RAR2 expression in APL-de-
rived cells (162). These results suggest that repression of
gene expression by oncogenic PML-RAR involves recruit-
ment of Dnmts to target loci as well as direct association with
HDAC complexes. The additional interactions among Dnmts,
MBDs, and HDACs assembled at these loci may cooperate
to ensure transcriptional repression of putative tumor sup-
pressor genes.
Conclusions
Although the relationships between DNA methylation, chro-
matin remodeling, and transcription repression have now
been established convincingly, conflicting observations still
fuel skepticism regarding the role of DNA methylation in
cancer. Overexpression of DNA (cytosine-5) methyltrans-
ferases is not invariably detected in tumor tissues in which
DNA methylation abnormalities exist. Tumor cells exhibit
both DNA hyper- and hypomethylation abnormalities, mak-
ing mechanisms based on increased methyltransferase ac-
tivity difficult to reconcile. Furthermore, somatic inactivation
of DNMT1 by homologous recombination in human colorec-
tal carcinoma cells leads to a dramatic decrease in DNA
(cytosine-5) methyltransferase activity; yet, these cells main-
tain the hypermethylated status of the p16
INK4a tumor sup-
pressor gene, demonstrating that Dnmt1 is not necessary for
maintenance of this DNA methylation abnormality (166). Re-
garding these points, it is important to keep in mind that the
properties of tumor cells represent an end-state of a process,
and they do not necessarily reflect the combination of ab-
normalities that participate in tumor development. Therefore,
DNA (cytosine-5) methyltransferase levels and global meth-
ylation patterns in tumor cells do not necessarily reflect their
progressive abnormalities that contributed to the evolution of
the tumor. As reviewed above, CpG methylation patterns are
influenced by numerous cooperating pathways, including de
novo and maintenance methylation, demethylation, and fac-
tors that may direct or prevent methylation of appropriate
and inappropriate targets, respectively. Cancer is a disease
involving both genetic and epigenetic abnormalities. Numer-
ous cellular events promote mutagenic “hits” within gene
targets that initiate or promote tumorigenesis. Likewise, ab-
normalities within the complex pathways that are linked to
DNA methylation can lead to several simultaneous “hits”
within the epigenome, altering expression of numerous
genes by modulating chromatin structure (Fig. 2). The current
explosion of data relating to the complex pathways that
target, maintain, and interpret epigenetic information en-
coded by DNA methylation promises a more comprehensive
understanding of the process of tumorigenesis. Bacteria may
not have chromatin, but they do not get cancer either.
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